The effects of novel antipsychotics on glucose and lipid levels

Journal of Clinical Psychiatry

Volumn 63, Issue 10, 2002, Pages 856-865

  Wirshing, Donna A ^a   Boyd, Jennifer A ^a   Meng, Laura R ^a   Ballon, Jacob S ^a   Marder, Stephen R ^a   Wirshing, William C ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETAZOLAMIDE; ASPARAGINASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; ESTROGEN; FLUPHENAZINE; GLYCEROL; HALOPERIDOL; INDAPAMIDE; INTERFERON; ISOTRETINOIN; LITHIUM; LOOP DIURETIC AGENT; METOLAZONE; MINOXIDIL; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PHENYTOIN; PROTEINASE INHIBITOR; QUETIAPINE; RISPERIDONE; THIAZIDE DIURETIC AGENT; THIORIDAZINE; UNINDEXED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY RISK; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0036774638     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n1002     Document Type: Article

References (61)

1. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363
2. Allison DB, Mentore JL, Heo M, et al. Antipsychotics-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
3. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
4. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine [letter]. Am J Psychiatry 1994;151:1395
5. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment [letter]. Am J Psychiatry 1994;151:1520-1521
6. Kostakoglu AE, Yazici KM, Erbas T, et al. Ketoacidosis as a side-effect of clozapine: A case report. Acta Psychiatr Scand 1996;93:217-218
7. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment [letter]. Am J Psychiatry 1996;153:737-738
8. Popli AP, Konicki PE, Jurjus GJ, et al. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111
9. Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997;32:168-170
10. Hägg S. Joelsson L. Mjörndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998;59:294-299
11. Ai D, Roper T, Riley J. Diabetic ketoacidosis and clozapine. Postgrad Med J 1998;74:493-494
12. Mohan D, Gordon H, Hindley N, et al. Schizophrenia and diabetes mellitus [letter]. Br J Psychiatry 1999;174:180-181
13. Colli A, Cocciolo M, Francobandiera F, et al. Diabetic ketoacidosis associated with clozapine treatment [letter]. Diabetes Care 1999;22:176-177
14. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999;60:783-791
15. Fertig MK, Brooks VG, Shelton PS, et al. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998;59:687-689
16. Ober SK, Hudnak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999;156:970
17. Gatta B, Ragalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment [letter]. Diabetes Care 1999;22:1002-1003
18. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:2079-2081
19. Gaulin BD, Markowitz JS, Caley CF. et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-1272
20. Spivak B, Lamschtein C, Talmon Y, et al. The impact of clozapine on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 1999;22:98-101
21. Dursun SM, Szemis A, Andrews H, et al. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study. J Psychiatry Neurosci 1999;24:453-455
22. Ghaeli P, Dufresne R. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 1999;19:1099-1101
23. Sheitman BB, Bird PM, Binz W, et al. Olanzapine-induced elevation of plasma triglyceride levels [letter]. Am J Psychiatry 1999;156:1471-1472
24. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770
25. Wirshing DA, Erhart SM, Pierre JM, et al. Nonextrapyramidal side effects of novel antipsychotics. Curr Opin Psychiatry 2000;13:45-50
26. Wirshing DA, Boyd J, Pien J. Weight gain and atypical antipsychotics. Essential Psychopharmacol. In press
27. Lindenmayer J-P, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999;156:1471
28. Von Hayek D, Huttl V, Reiss J, et al. Hyperglycemia and ketoacidosis associated with olanzapine. Nervenarzt 1999;70:836-837
29. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443
30. Henderson D, Cagliero E, Gray C. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975-981
31. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001;111:716-723
32. Sobel M, Jagger ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. J Clin Psychiatry 1999;60:556-557
33. Wilson D. New onset diabetes and ketoacidosis with atypical antipsychotics. Presented at the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; May 30-June 2, 2000; Boca Raton, Fla
34. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment [letter]. Psychosomatics 2000;41:369-370
35. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new onset diabetes. Biol Psychiatry 2001;50:148-149
36. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993;328:313-318
37. Drexel H, Amann FW, Beran J, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994;90:2230-2235
38. Consensus conference: Treatment of hypertriglyceridemia. JAMA 1984;251:1196-1200
39. Risperdal [Package Insert]. Titusville, NJ: Janssen Pharmaceutica; 1999
40. Seroquel [Package Insert]. Wilmington, Del: AstraZeneca Pharmaceuticals; 2001
41. SAS Institute. SAS/STAT User's Guide, Version 6.12, vol 1, 4th ed. Cary, NC: SAS Institute; 1989:943
42. American Diabetes Association Screening for Type 2 Diabetes. Diabetes Care 2000;23(suppl 1):S1-S116
43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023
44. Wirshing DA. Weight gain associated with novel antipsychotics. Prim Psychiatry 2000;7:59-62
45. Rockwell WJ, Ellinwood EH, Trader DW. Psychotropic drugs promoting weight gain: Health risks and treatment implications. South Med J 1983;76:1407-1412
46. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(suppl 21):25-30
47. Klett C, Caffey E. Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatry 1960;2:102-108
48. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics, Br J Psychiatry 1988;153:214-217
49. Bemstein J. Psychotropic drug induced weight gain: Mechanism and management. Clin Neuropharmacol 1988;11(suppl 1):S194-S206
50. Brady KT Weight gain associated with psychotropic drugs. South Med J 1989;82:611-617
51. 2c serotonin receptors. Nature 1995;374:542-546
52. Garattini S, Mennini T, Samain R. Reduction of food intake by manipulation of central serotonin: Current experimental results. Br J Psychiatry 1989;155(suppl 8):41-51
53. Knight A. Astemizole: A new non-sedating antihistamine for hayfever. J Otolaryngol 1985;14:85-88
54. Schotte A, Janssen PF. Megens AA, et al. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res 1993;631:191-202
55. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312-314
56. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998;106:475-477
57. Uvnas-Moberg K, Ahlenius S, Alster P, et al. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagon in the rat. Neuroendocrinology 1996;63:269-274
58. Sugimoto Y, Yamada J, Kimura I, et al. The effects of serotonin 1A receptor agonist buspirone on tolbutamide-induced hypoglycemia in rats. Biol Pharm Bull 1995;18:1296-1298
59. Wozniak KM, Linnoila M. Hyperglycemia properties of serotonin receptor antagonists. Life Sci 1991;49:101-109
60. Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001;62(suppl 27):5-9
61. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999;18:99-104